Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$48.24 USD
+1.84 (3.97%)
Updated Nov 22, 2024 04:00 PM ET
After-Market: $48.10 -0.14 (-0.29%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TARS 48.24 +1.84(3.97%)
Will TARS be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for TARS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARS
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
TARS: What are Zacks experts saying now?
Zacks Private Portfolio Services
2seventy bio, Inc. (TSVT) Reports Q3 Loss, Lags Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains?
Other News for TARS
Ikarian Capital, LLC Adjusts Stake in iBio Inc
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
Prudential Financial Inc's Strategic Acquisition in Tarsus Pharmaceuticals Inc
Paradigm Biocapital Advisors LP Increases Stake in Tarsus Pharmaceuticals Inc
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in LianBio